What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?

Brian Wojciechowski, M.D., practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer. In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer: Ibrance (chemical name: palbociclib) Kisqali (chemical name: ribociclib) Verzenio (chemical name: abemaciclib) may cause rare but serious inflammation in the lungs. Listen to the podcast to hear Dr. Wojciechowski talk about: how CDK4/6 inhibitors are used to treat breast cancer why we’re just hearing about this side effect now the recommendations for anyone being treated with a CDK4/6 inhibitor